DK1689706T3 - Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser - Google Patents

Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser Download PDF

Info

Publication number
DK1689706T3
DK1689706T3 DK04816944.5T DK04816944T DK1689706T3 DK 1689706 T3 DK1689706 T3 DK 1689706T3 DK 04816944 T DK04816944 T DK 04816944T DK 1689706 T3 DK1689706 T3 DK 1689706T3
Authority
DK
Denmark
Prior art keywords
beta
alpha
treatment
proliferative disorders
unsaturated sulfoxides
Prior art date
Application number
DK04816944.5T
Other languages
Danish (da)
English (en)
Inventor
Premkumar E Reddy
Ramana M V Reddy
Stanley C Bell
Original Assignee
Temple Univ - Of The Commonwealth System Of Higher Education
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ - Of The Commonwealth System Of Higher Education, Onconova Therapeutics Inc filed Critical Temple Univ - Of The Commonwealth System Of Higher Education
Application granted granted Critical
Publication of DK1689706T3 publication Critical patent/DK1689706T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK04816944.5T 2003-11-14 2004-11-08 Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser DK1689706T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52052303P 2003-11-14 2003-11-14
PCT/US2004/037293 WO2005046599A2 (en) 2003-11-14 2004-11-08 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders

Publications (1)

Publication Number Publication Date
DK1689706T3 true DK1689706T3 (da) 2017-04-03

Family

ID=34590471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04816944.5T DK1689706T3 (da) 2003-11-14 2004-11-08 Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser

Country Status (12)

Country Link
US (1) US7744889B2 (https=)
EP (1) EP1689706B1 (https=)
JP (1) JP5196787B2 (https=)
KR (1) KR20060109871A (https=)
AU (1) AU2004289281C1 (https=)
CA (1) CA2546495C (https=)
DK (1) DK1689706T3 (https=)
ES (1) ES2621802T3 (https=)
HU (1) HUE032523T2 (https=)
IL (1) IL174426A (https=)
NZ (1) NZ545995A (https=)
WO (1) WO2005046599A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549962A (en) * 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
JP5156389B2 (ja) * 2005-01-05 2013-03-06 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 薬剤耐性増殖性疾患の治療剤
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007005670A2 (en) * 2005-06-30 2007-01-11 The Research Foundation Of The State University Of New York Natural and synthetic sulfoxide, selenone and selenoxide analogs and polymer conjugated forms thereof for the modulation of angiogenesis
US20110250184A1 (en) * 2008-12-16 2011-10-13 Onconova Therapeutics ,Inc. Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
EP2486923B1 (en) * 2011-02-11 2015-09-09 Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG Histone deacetylase (HDAC) inhibiting compounds and method of making same
AU2013318206B2 (en) 2012-09-20 2018-07-26 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
AU2014262764B2 (en) * 2013-05-07 2018-11-15 The Regents Of The University Of California Radiomitigating pharmaceutical formulations
CN104892471B (zh) * 2015-05-15 2020-03-27 中国人民解放军军事医学科学院放射与辐射医学研究所 具有蛋白酪氨酸激酶抑制活性的物质、其制备方法及用途
US10383831B2 (en) * 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865867A (en) 1967-06-19 1975-02-11 Monsanto Co Meta-bifunctional benzenes
US3975435A (en) 1974-03-06 1976-08-17 Givaudan Corporation Substituted cinnamanilides
DK586175A (da) * 1974-12-28 1976-06-29 Asahi Chemical Ind Cephalosporin-forbindelser
JPH05262733A (ja) * 1992-03-23 1993-10-12 Sapporo Breweries Ltd 含硫黄化合物，その製造法及びそれを有効成分とする抗潰瘍剤
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
IL164568A0 (en) 1997-05-14 2005-12-18 Atherogenics Inc Compounds and methods for the inhibition of the expression of vcam-1
CN1163480C (zh) * 1997-10-03 2004-08-25 坦普尔大学 苯乙烯砜抗癌剂
US6548553B2 (en) * 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
JP4596651B2 (ja) * 1999-04-02 2010-12-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｅ）−スチリルスルホン抗癌剤
US6762207B1 (en) 1999-04-02 2004-07-13 Temple University - Of The Commonwealth System Of Higher Education (E)-styryl sulfone anticancer agents
JP2002541101A (ja) * 1999-04-02 2002-12-03 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
US6117364A (en) 1999-05-27 2000-09-12 Nalco/Exxon Energy Chemicals, L.P. Acid corrosion inhibitor
EP1191929A4 (en) 1999-06-16 2005-02-16 Univ Temple (Z) -STYRYL ACETOXYPHENYL SULFIDES AS INHIBITORS OF CYCLO-OXYGENASE
WO2001026645A1 (en) * 1999-10-12 2001-04-19 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6767926B1 (en) * 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6541475B2 (en) 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
AU2001296677A1 (en) 2000-10-05 2002-04-15 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
DE60112466D1 (de) * 2000-10-12 2005-09-08 Yamaha Motor Co Ltd Mischer für gasförmige brennstoffe
JP2004521126A (ja) * 2001-02-27 2004-07-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用
AU2002306604B2 (en) 2001-02-28 2007-09-13 Onconova Therapeutics, Inc. N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
WO2002069892A2 (en) * 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
NZ549962A (en) * 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
WO2006104668A2 (en) 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases

Also Published As

Publication number Publication date
ES2621802T3 (es) 2017-07-05
JP2007513877A (ja) 2007-05-31
EP1689706A4 (en) 2007-11-14
HUE032523T2 (en) 2017-09-28
WO2005046599A2 (en) 2005-05-26
EP1689706B1 (en) 2017-01-11
JP5196787B2 (ja) 2013-05-15
AU2004289281B2 (en) 2011-05-26
EP1689706A2 (en) 2006-08-16
NZ545995A (en) 2009-04-30
US20060280746A1 (en) 2006-12-14
CA2546495C (en) 2012-10-09
AU2004289281C1 (en) 2011-12-08
WO2005046599A3 (en) 2005-10-06
CA2546495A1 (en) 2005-05-26
KR20060109871A (ko) 2006-10-23
AU2004289281A1 (en) 2005-05-26
IL174426A0 (en) 2006-08-01
IL174426A (en) 2012-01-31
US7744889B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
NL1029015A1 (nl) Therapeutische verbindingen.
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK1553929T3 (da) Sammensætning med kontrolleret frigivelse.
DK1446122T5 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
ES2356376T8 (es) Procedimiento cosmetico para las axilas.
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
ES1053304Y (es) Disposicion mejorada para la fijacion de fregaderos.
DK1689706T3 (da) Alfa, beta-umættede sulfoxider til behandling af proliferative forstyrrelser
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK2845594T3 (da) Anvendelse af dihydroimidazoloner til behandlingen af hunde.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
NO20053156D0 (no) Anvendelse av ostrogen reseptor alfa modulatorer for behandling av multippel sklerose.
ES1058317Y (es) Kit para la fabricacion de balaustres.
DK1594498T3 (da) Anvendelse af etazolat til behandling af sygdomme
ES1053767Y (es) Conjunto de piezas ceramicas de construccion, prensadas, para la ejecucion de paramentos.
ES1052073Y (es) Urna desmontable.